Stock Market Reviews

CMPX (Compass Therapeutics, Inc.) News

Get the latest news, insights, and market updates on CMPX (Compass Therapeutics, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update
  In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in pat
  Aug 11, 2025 - $CMPX
• Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
  BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Call Details: Date: M
  Aug 8, 2025 - $CMPX
• Stifel Keeps Buy Rating on Compass Therapeutics (CMPX)
  Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Performing Penny Stocks So Far in 2025. On July 14, Stifel reiterated its “Buy” rating for Compass Therapeutics, Inc. (NASDAQ:CMPX) with a price target of $11. This decision came after investor meetings with the company’s management. According to the research firm, the extended timeline for […]
  Jul 25, 2025 - $CMPX
• Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline
  Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the top high-return penny stocks to buy now. On July 14, Stifel reiterated its Buy rating and $11.00 price target for CMPX. The firm views the extended timeline for topline data from the Phase 2/3 COMPANION-002 trial—now expected in Q4 2025—as a positive, given the 19-month follow-up in […]
  Jul 22, 2025 - $CMPX
• Compass Therapeutics And 2 Other Promising Penny Stocks To Watch
  The market has stayed flat over the past week, but it's up 11% over the past year, with earnings forecasted to grow by 15% annually. Penny stocks may be a throwback term, but they represent opportunities that are far from outdated. With strong balance sheets and solid fundamentals, these smaller or newer companies can offer growth potential at lower price points, making them intriguing options for investors seeking hidden gems in today's market.
  Jul 15, 2025 - $CMPX
• Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist
  Over the last 7 days, the United States market has risen by 1.2%, and over the past year, it has climbed by 11%, with earnings forecasted to grow annually by 14%. In this context of growth, identifying good stocks often means looking for those with strong financial health and potential for long-term success. Penny stocks, though an outdated term in some respects, remain relevant as they often represent smaller or newer companies that can offer unique growth opportunities when backed by solid...
  Jun 12, 2025 - $CMPX